Results 111 to 120 of about 43,749 (262)

Bowel Obstruction/Ileus Associated With the Use of Glucagon‐Like Peptide‐1 Receptor Agonists: A Nationwide Database Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo, Akira Okada, Takashi Sakamoto, Hideo Yasunaga   +3 more
wiley   +1 more source

Mineralocorticoid receptor antagonists in dialysis patients after ACHIEVE and ALCHEMIST: updated systematic review and meta-analysis of 14 randomized trials. [PDF]

Ren Fail
Zhu Y, Li J, Huang Z, Qiu F.
europepmc   +1 more source

Histopathological stratification of primary aldosteronism using the CYP11B2 size ratio: first evaluation in clinical routine

Histopathology, EarlyView.
CYP11B2 immunohistochemistry identifies aldosterone‐producing nodules and enables objective subtyping using the B2 ratio (B2R), defined as the size ratio between the largest and second‐largest CYP11B2‐positive nodules. A B2R ≥8.1 indicates classical histology with a dominant lesion and high likelihood of cure, whereas B2R <8.1 reflects non‐classical ...
Adam Stenman, Tim Nilsson, Henrik Falhammar, C. Christofer Juhlin   +3 more
wiley   +1 more source

Changes in Pulmonary Artery Pressure Following Initiation of Guideline-Directed Medical Therapies in Patients With Heart Failure: Insights From GUIDE-HF. [PDF]

Circ Heart Fail
Desai AS, Zile MR, Ducharme A, Mehra MR, Maisel AS, Sears SF, Costanzo MR, Smart FW, Chien CV, Jonsson O, Hall S, Nie H, Lee FS, Lindenfeld J.   +13 more
europepmc   +1 more source

Improving primary aldosteronism diagnosis and treatment: outcomes from an endocrine hypertension service

Internal Medicine Journal, EarlyView.
Abstract Aims To evaluate the sustained impact of the Endocrine Hypertension Service on primary aldosteronism (PA) diagnosis and management over a subsequent 3‐year period. Background PA is a prevalent yet underdiagnosed cause of secondary hypertension, associated with increased cardiovascular, renal and metabolic risk. Limited awareness, resources and
Minn W. Chow, Chrislyn Ng, Jimmy Shen, Peter J. Fuller, Jun Yang, Renata Libianto   +5 more
wiley   +1 more source

Apparent mineralocorticoid excess with a novel <i>HSD11B2</i> variant: longitudinal clinical and biochemical follow-Up. [PDF]

JCEM Case Rep
Nalluri BT, Kudugunti N, Sahay RK.
europepmc   +1 more source

At the heart of home‐based care: multidisciplinary heart failure management in a quaternary centre's community programmes

Internal Medicine Journal, EarlyView.
Abstract Background Heart failure (HF) is a frequent cause of hospital admissions, carrying a high risk of hospital readmission and mortality. Alfred Health General Medicine Hospital in the Home (GM‐HITH) and Hospital Admission Risk Program (HARP) offer multidisciplinary HF care to multimorbid patients in bed‐substitution and non‐admitted community ...
Elana Forbes, Ingrid Hopper, Cathy Corbett, Felice Borghmans, Emma O'Donnell, Ana Slavnic, Genevieve Harvey, Elizabeth Rochford, Archana Thayaparan   +8 more
wiley   +1 more source

Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: Clinical Evidence, Pharmacology, and Drug-Drug Interactions for Personalized Management of Hyperkalemia. [PDF]

Int J Mol Sci
Hirai T, Katayama K.
europepmc   +1 more source

Associations of finerenone with reduced insulin resistance in patients with type 2 diabetes and chronic kidney disease: A real‐world observational study

Journal of Diabetes Investigation, EarlyView.
This real‐world observational study enrolled 256 patients with type 2 diabetes and chronic kidney disease (T2D‐CKD). After 12 months of finerenone treatment, 45 patients completed follow‐up. Finerenone was associated with significant improvements in insulin resistance markers (HOMA‐IR, TyG index), lipid profile (LDL‐C), glycemic control (HbA1c), and ...
Xin Zhao, Bohan Liu, Ran Sun, Yaxuan Shi, Ya Liu   +4 more
wiley   +1 more source

Mineralocorticoid receptor antagonists in heart failure with sustained monomorphic ventricular tachycardia: comparative analysis of spironolactone versus eplerenone. [PDF]

Open Heart
Szakál I, Komlósi F, Tóth P, Arnóth B, Bohus G, Vámosi P, Szegedi N, Salló Z, Osztheimer I, Perge P, Orbán G, Kardos A, Merkely B, Gellér L, Nagy KV.   +14 more
europepmc   +1 more source